T-cell receptor-β V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York, NY : Springer International, c1982-

Genes, T-Cell Receptor/*genetics ; Neoplasms/*genetics ; Receptors, Antigen, T-Cell, alpha-beta/*genetics; Alleles ; Humans ; Neoplasms/mortality ; Neoplasms/pathology ; Survival Rate

Class I and class II HLA proteins, respectively, have been associated with subsets of V(D)J usage resulting from recombination of the T-cell receptor (TCR) genes. Additionally, particular HLA alleles, in combination with dominant TCR V(D)J recombinations, have been associated with several autoimmune diseases. The recovery of TCR recombination reads from tumor specimen exome files has allowed rapid and extensive assessments of V(D)J usage, likely for cancer resident T-cells, across relatively large cancer datasets. The results from this approach, in this report, have permitted an extensive alignment of TCR-β VDJ usage and HLA class I and II alleles. Results indicate the correlation of both better and worse cancer survival rates with particular TCR-β, V and J usage-HLA allele combinations, with differences in median survival times ranging from 7 to 130 months, depending on the cancer and the specific TCR-β V and J usage/HLA class allele combination.

Cancer Inform. 2016 Feb 25;15:23-8. (PMID: 26966347)
Hum Vaccin Immunother. 2017 Mar 4;13(3):501-506. (PMID: 28085544)
J Clin Oncol. 2010 Oct 10;28(29):4531-8. (PMID: 20516428)
J Leukoc Biol. 1995 Apr;57(4):536-42. (PMID: 7722411)
EBioMedicine. 2015 Nov 17;2(12):2037-45. (PMID: 26844284)
J Biol Response Mod. 1990 Aug;9(4):431-8. (PMID: 2395007)
Lab Invest. 2017 Dec;97(12):1516-1520. (PMID: 28805806)
Am J Surg. 1968 Mar;115(3):371-5. (PMID: 5640567)
Sci Rep. 2017 Sep 12;7(1):11301. (PMID: 28900149)
Nature. 2017 Jul 6;547(7661):94-98. (PMID: 28636589)
PLoS Pathog. 2010 Nov 18;6(11):e1001198. (PMID: 21124993)
Am J Transplant. 2016 Nov;16(11):3131-3138. (PMID: 27273900)
Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6506-10. (PMID: 1378629)
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8059-8064. (PMID: 28674023)
Ann Med Surg (Lond). 2015 Aug 04;4(3):248-53. (PMID: 26288728)
Nucleic Acids Res. 2018 Jan 4;46(D1):D419-D427. (PMID: 28977646)
J Exp Med. 1986 Jul 1;164(1):90-103. (PMID: 3088203)
Am J Forensic Med Pathol. 1982 Sep;3(3):259-64. (PMID: 7148780)
J Immunol. 2015 Nov 15;195(10):4604-14. (PMID: 26423148)
Ann Intern Med. 1978 Jun;88(6):796-8. (PMID: 666136)
Cancer Immunol Immunother. 2017 Mar;66(3):403-410. (PMID: 27995306)
Diagn Histopathol. 1981 Apr-Jun;4(2):157-74. (PMID: 7021114)
Curr Opin Immunol. 2002 Feb;14(1):52-65. (PMID: 11790533)
PLoS One. 2015 Oct 30;10(10):e0140815. (PMID: 26517366)
Immunol Cell Biol. 2011 Mar;89(3):375-87. (PMID: 21301479)
J Exp Med. 1994 Sep 1;180(3):1097-106. (PMID: 7520467)
Bioinformatics. 2014 Dec 1;30(23):3310-6. (PMID: 25143287)
Eur J Immunol. 2010 Sep;40(9):2470-81. (PMID: 20690181)

Keywords: Cancer survival.; HLA class I and class II; T-cell receptor; V and J segment usage

0 (Receptors, Antigen, T-Cell, alpha-beta)

Date Created: 20180307 Date Completed: 20181211 Latest Revision: 20240426

20240426

PMC11028132

10.1007/s00262-018-2139-7

29508024